Relationship between Chemotherapy and Atrial Fibrillation: Clinical Case
A. A. Avagimyan,
L. H. Mkrtchyan,
A. A. Gevorkyan,
N. B. Kononchuk,
L. V. Kakturskiy,
Z. T. Djndoyan Abstract
The aim of this article is to represent the characterization of the clinical case of chemotherapy-related atrial fibrillation (AF) development in the young woman, elaborated as a result of multiple neoadjuvant and adjuvant modes of the intake of chemotherapy (both anthracycline based and non-anthracycline ones). In this case, the noted disturbances of heart rhythm should be recognized as a manifestation of cardiotoxicity. The latter implies the degree of detrimental effect of chemotherapeutical medication on the morphophynctional parameters of the cardiovascular system. Anthracycline drugs, being highly effective chemotherapytical agents, provide well-known toxic effects on the heart and vessels. Anthracycline mediated cardiotoxicity is a well- known veracity that dates back to the 60s of the last century, but up to now this medication sustains irreplaceable components of big volume of chemotherapy modes. Moreover, it should be noted that relatively newer drugs also posses certain cardiotoxicogenic potential.
About the Authors
A. A. Avagimyan
Yerevan State Medical University after M. Heratsi
Armenia
Armenia
Ashot A. Avagimyan
Yerevan
L. H. Mkrtchyan
Yerevan State Medical University after M. Heratsi
Armenia
Armenia
Lusine H. Mkrtchyan
Yerevan
A. A. Gevorkyan
Yerevan State Medical University after M. Heratsi
Armenia
Armenia
Astgik A. Gevorkyan
Yerevan
N. B. Kononchuk
Minsk City Clinical Hospital of Emergency Care
Belarus
Belarus
Natalia B. Kononchuk
L. V. Kakturskiy
Research Institute of Human Morphology
Russian Federation
Russian Federation
Lev V. Kakturskiy
Moscow
Z. T. Djndoyan
Yerevan State Medical University after M. Heratsi
Armenia
Armenia
Zinaida T. Djndoyan
Yerevan
References
1. Bhagat A, Kleinerman ES. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. Adv Exp Med Biol. 2020;12(57):181-92. DOI:10.1007/978-3-030-43032-0_15.
2. Gilchrist SC, Barac A, Ades PA, et al. American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. Circulation. 2019;139(21):997-1012. DOI:10.1161/CIR.0000000000000679.
3. Campia U, Moslehi JJ, Amiri-Kordestani L, et al. Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. Circulation. 2019;139(13):e579-e602. DOI:10.1161/CIR.0000000000000641.
4. Avagimyan A, Kakturskiy L, Heshmat-Ghahdarijani K, et al. Anthracycline Associated Disturbances of Cardiovascular Homeostasis. Curr Probl Cardiol. 2021 May 29;100909. DOI:10.1016/j.cpcardiol.2021.100909.
5. Kirkham AA, Beaudry RI, Paterson DI, et al. Curing breast cancer and killing the heart: A novel model to explain elevated cardiovascular disease and mortality risk among women with early stage breast cancer. Prog Cardiovasc Dis. 2019;62(1):116-29. DOI:10.1016/j.pcad.2019.02.002
6. He H, Luo Y, Qiao Y, et al. Curcumin attenuates doxorubicin-induced cardiotoxicity via suppressing oxidative stress and preventing mitochondrial dysfunction mediated by 14-3-3γ. Food Funct. 2018;9(8):4404-18. DOI:10.1039/c8fo00466h.
7. Zhang L, Zhu K, Zeng H, et al. Resveratrol solid lipid nanoparticles to trigger credible inhibition of doxorubicin cardiotoxicity. Int J Nanomedicine. 2019;14(2):6061-71. DOI:10.2147/IJN.S211130.
8. Khan M, Shobha JC, Mohan IK, et al. Protective effect of Spirulina against doxorubicin-induced cardiotoxicity. Phytother Res. 2005;19(12):1030-7. DOI:10.1002/ptr.1783.
9. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al.ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular tox icity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-801. DOI:10.1093/eurheartj/ehw211.
10. Słowik A, Jagielski P, Potocki P, et al. Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study. Kardiol Pol. 2020;78(2):131-7. DOI:10.33963/KP.15163.
11. Curigliano G, Lenihan D, Fradley M, et al. ESMO Guidelines Committee. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-90. DOI:10.1016/j.annonc.2019.10.023.
12. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017;33(11):1342-433. DOI:10.1016/j.cjca.2017.08.022.
13. Čelutkienė J, Pudil R, López-Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22(9):1504-24. DOI:10.1002/ejhf.1957.
14. Qi W, Boliang W, Xiaoxi T, et. Cardamonin protects against doxorubicin-induced cardiotoxicity in mice by restraining oxidative stress and inflammation associated with Nrf2 signaling. Biomed Pharmacother. 2020;122:109547. DOI:10.1016/j.biopha.2019.109547.
15. Avagimyan A, Mrochek A, Sarrafzadegan N, et al. Mitochondrial dysfunction associated with AC mode of chemotherapy intake. European Heart Journal. 2020;41suppl.2:ehaa946.3293. DOI:10.1093/ehjci/ehaa946.3293.
16. Alizadehasl A, Ghadimi N, Kaveh S, et al. Prevention of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis. Int J Clin Pharm. 2021;43(1):25-34. DOI:10.1007/s11096-020-01146-6.
17. Schlitt A, Jordan K, Vordermark D, et al. Cardiotoxicity and oncological treatments. Dtsch Arztebl Int. 2014;111(10):161-8. DOI:10.3238/arztebl.2014.0161.
18. Armenian S, Bhatia S. Predicting and Preventing Anthracycline-Related Cardiotoxicity. Am Soc Clin Oncol Educ Book. 2018;23(38):3-12. DOI:10.1200/EDBK_100015.
19. Armenian SH, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893-911. DOI:10.1200/JCO.2016.70.5400.
20. Nemeth BT, Varga ZV, Wu WJ, Pacher P. Trastuzumab cardiotoxicity: from clinical trials to experimental studies. Br J Pharmacol. 2017;174(21):3727-48. DOI:10.1111/bph.13643.
21. Barish R, Gates E, Barac A. Trastuzumab-Induced Cardiomyopathy. Cardiol Clin. 2019;37(4):407-18. DOI:10.1016/j.ccl.2019.07.005.
22. Johnson TA, Singla DK. Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker. Can J Physiol Pharmacol. 2018;96(7):647-54. DOI:10.1139/cjpp-2018-0005.
23. Porta-Sánchez A, Gilbert C, Spears D, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017;6(12):e007724. DOI:10.1161/JAHA.117.007724.
24. Avagimyan A. The Novel Visibility of Myocarditis from Pathology to Treatment. Aristotele Biomedical Journal. 2019;1(1):31-47. DOI:10.25040/lkv2019.04.051.
25. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474-502. DOI:10.1038/s41569-020-0348-1.
26. Benjanuwattra J, Siri-Angkul N, Chattipakorn SC, Chattipakorn N. Doxorubicin and its proarrhythmic effects: A comprehensive review of the evidence from experimental and clinical studies. Pharmacol Res. 2020; 151:104542. DOI:10.1016/j.phrs.2019.104542.
27. Damiani RM, Moura DJ, Viau CM, et al. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch Toxicol. 2016;90(9):2063-76. DOI:10.1007/s00204-016-1759-y.
Review
For citations:
Avagimyan A.A., Mkrtchyan L.H., Gevorkyan A.A., Kononchuk N.B., Kakturskiy L.V., Djndoyan Z.T. Relationship between Chemotherapy and Atrial Fibrillation: Clinical Case. Rational Pharmacotherapy in Cardiology. 2021;17(5):785-791. (In Russ.) https://doi.org/10.20996/1819-6446-2021-10-17
Views: 21487
Email this article 